Files and links (1)
Published VersionCC BY-NC V4.0, Open Access
Journal article
Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
Human Vaccines & Immunotherapeutics, Vol.20(1), pp.1-10
2024
Abstract
Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.
Details
- Title
- Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
- Authors
- Quanlan Fu (Author) - Guizhou UniversityYuandong Luo (Author) - Guizhou UniversityJunjie Li (Author) - Zhongao Bio-pharmaceutical Technology Co., Ltd. (China)Pingping Zhang (Author) - First People's Hospital of FoshanShuxian Tang (Author) - First People's Hospital of FoshanXinyi Song (Author) - Guangdong Pharmaceutical UniversityJiawei Fu (Author) - Guangdong Pharmaceutical UniversityMengqi Liu (Author) - Guizhou UniversityRongmi Mo (Author) - Guangdong Pharmaceutical UniversityMing Wei (Author) - Griffith UniversityHejie Li (Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationXiaosong Liu (Author) - Zhongao Bio-pharmaceutical Technology Co., Ltd. (China)Tianfang Wang (Corresponding Author) - University of the Sunshine Coast, Queensland, Centre for BioinnovationGuoying Ni (Corresponding Author) - Zhongao Bio-pharmaceutical Technology Co., Ltd. (China)
- Publication details
- Human Vaccines & Immunotherapeutics, Vol.20(1), pp.1-10
- Publisher
- Taylor & Francis Inc.
- Date published
- 2024
- DOI
- 10.1080/21645515.2024.2385654
- ISSN
- 2164-554X; 2164-5515
- Copyright note
- © 2024 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
- Grant note
- This study was supported in part by Deng Feng project of Foshan First People’s Hospital [2019A008], National Science Foundation of Guangdong province [2020A1515010855] and National Natural Science Foundation of China [31971355].
- Organisation Unit
- School of Science and Engineering - Legacy; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 991057366402621
- Output Type
- Journal article
Metrics
21 Record Views